β2-AR signaling controls trastuzumab resistance-dependent pathway
1Department of Pathophysiology, Institute of Basic Medical Sciences, Beijing, China.
Oncogene
|March 24, 2015
Summary
Beta-2 adrenergic receptor (β2-AR) activation by catecholamines promotes trastuzumab resistance in Her2-positive breast cancer. Blocking β2-AR with propranolol may improve treatment response and survival rates.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Trastuzumab resistance is a significant challenge in treating Her2-overexpressing breast cancer.
- The molecular mechanisms driving this resistance are not fully understood.
- Previous work identified a positive feedback loop between β2-adrenergic receptor (β2-AR) and Her2, suggesting a role for β2-AR in resistance.
Purpose of the Study:
- To investigate the role of β2-AR activation in trastuzumab resistance in Her2-overexpressing breast cancer.
- To identify molecular pathways involved in catecholamine-induced trastuzumab resistance.
- To evaluate the therapeutic potential of combining trastuzumab with β-blockers.
Main Methods:
- Correlative analysis of β2-AR expression and trastuzumab response in patients.
- In vitro and in vivo experiments assessing the effects of catecholamines on trastuzumab efficacy.
- Molecular analyses including gene/microRNA expression, Western blotting, and pathway activation studies (STAT3, PI3K/Akt, mTOR).
- Retrospective clinical study evaluating combination therapy with trastuzumab and β-blockers.
Main Results:
- β2-AR expression negatively correlated with trastuzumab response in patients.
- Catecholamines antagonized trastuzumab's anti-proliferative effects by upregulating miR-21 and MUC-1 via Her2/STAT3, leading to PI3K/Akt activation.
- Catecholamines induced mTOR activation through inhibition of miR-199a/b-3p.
- The β-blocker propranolol enhanced trastuzumab's antitumor activity and re-sensitized resistant cells.
- Combination therapy with β-blocker and trastuzumab significantly improved progression-free and overall survival in metastatic breast cancer patients.
Conclusions:
- Catecholamine-induced β2-AR activation drives trastuzumab resistance through the PI3K/Akt/mTOR pathway.
- β2-AR serves as a predictive marker for trastuzumab treatment response.
- Combining β-blockers with trastuzumab is a promising therapeutic strategy for Her2-overexpressing breast cancer.
More Related Videos
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
2.9K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
4.2K
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
71
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
71
02:38Mitogens and the Cell Cycle
8.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
02:57Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
01:15Receptor Downregulation in MVBs
3.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
3.0K
01:16TGF - β Signaling Pathway
11.1K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
11.1K